8- The Michigan Daily - SPORTSMonday - Monday, March 21, 1994 Gymnasts close home season in style vs. GW 0 By MELANIE SCHUMAN DAILY SPORTS WRITER After Saturday night's decisive victory over George Washington, the Michigan women's gymnastics team finished the regular season with only one loss and its highest rank- ing in school history. An overall record of21-7, and 7- 0 in limited Big Ten competition, is probably better than Michigan coach Bev Plocki could have hoped for when she embarked on her fifth year guiding the Wolverines. Before the season, Plocki fo- cused on the conference meet as the a would-be climatic finish to an- other up-and-coming season for the Wolverines. A ninth-place finish at the NCAA Championships last year provided the motivation for Michigan, which predicted a 1994 final standing among the Super Six elite of NCAA gymnastics. As of the final week of competi- tion, Michigan is ranked No. 3, hav- ing overcome No. 4 and perennial national-title contender Alabama. Whether the Wolverines remain third is not exactly up to them. It depends on how other teams fared and whose composite (released Wednesday) will tally the highest. "We were pretty pleased," fresh- man Andrea McDonald said. "We try not to worry about scores we can't control. We got caught up in that for a while." McDonald placed second in the all-around against the Colonials with a 38.725, third on the uneven bars (9.775) and third on the balance beam (9.600). After an unsatisfac- tory week of practice, she was pleased with her effort. Michigan, which had hoped to come out strong on the vault to start the meet, did just that, as the team total of 49.125 was its second high- est for one individual event (floor score was 49.3). Junior Beth Wymer carried the Wolverines with a first-place all- around finish of 39.250, just shy of her nation-fbading 39.544 average. Wymer, who also leads the na- tion in bars, beam and floor exer- cise, dominated this weekend's No. 1 slot with high marks, including another perfect 10 on the floor. Senior Nicole Bronner, the most consistent all-arounder for the Colonials with an average score of 37.408, placed fifth with 37.8750, her highest mark on the season. Although finishing behind Wol- verines, she had three strong indi- vidual peformances on vault, bars and floor. The No. 41 Colonials may leave Ann Arbor with a loss on their score card, but they too managed to do just what they expected. Even with a few breaks, coach Margie Cunningham believes her squad's 188.525 (a season best) is a solid enough mark to retain its No. 7 regional seed. The Colonials' "nemesis all year" has been the uneven bars, and against Michigan, the event contin- ued to haunt them. "We can't let the individual things affect us as long as long as we can get the overall we need," Cunningham said. They found that "overall" they needed and so did Michigan. "(The season) is not over yet, so it doesn't even feel like it yet," said sophomore Wendy Marshall, after her winning performance on the beam (9.8). She also nailed a sec-@ ond-place routine on vault (9.9) in this final regular-season duel. 'Dianna Ranelli placed third this weekend on the floor with a 9.875. DEADLINE EXTENDED (there are children who need you) Teach For America is a national teacher corps which brings non-education majors into urban and rural public school classrooms across the country for a two year commitment. You do not need an education degree. You do need idealism, a willingness to work with at-risk children, the dedication to be a great teacher, and the desire to be part of a corps. Because the demand for Teach For America teachers has been so incredible this year, we have extended our application deadline until MARCH 25, 1994 However there are a limited number of applications, so you must act immediately! Applications may be available at your career service office. If not, call 1-800/832-1230, ext. 450. SUGIURA Continued from page 3 "(Winning the title) never crossed my mind," Webb says. "I was too preoccupied with being scared." The distance medley was the second-to-last race of the entire two-day meet. All Webb could do was wait and brew her cauldron of nervous energy. But by race time, Webb was ready. Pep talks from teammates and coaches had prepared her, and now she wanted to do her part. After the previous night's debacle, McClimon and Babcock were also ready to race. "I think Courtney and I both had revenge on our minds from the night before," McClimon says. There was no questioning whether Westerby was ready. When your nickname is "Beast," you don't have a lot of choice but to be fired up. "I remember Kristin Westerby saying, 'I'm running with the top. Not the competitors, but the people on my team,"' Webb recalls. "You think about 0 that, and if she feels that way about you, you have to feel that way about yourself." All that was left to do was run. After an entire season of pointing at this race as their shot at a title, after the disappointing 5,000, after the tragedy in the life of a friend, after the skittishness of a teammate running the biggest race of her life, all that was left was 4,000 meters of running to be shared by four women. They were the fastest entry, but now, they were running in a realm where seed times and the like hardly mattered. They were running against themselves. They call these things windows of opportunity. Only for these four athletes, it wasn't so much a window as it was something closer to the size of a porthole. But through the sheer force of their collective will, they crashed through like a battering ram, seizing the glory at the only instant that it was available to be seized. The race went off without a hitch. Westerby ran a solid leg and handed off to Webb, who peeled off a blistering 400. She handed off to McClimon, who completed her leg in third, giving Babcock a chance to run down the leaders. Babcock did, and finished in 11:08.60. As it was the event's first running at the indoor NCAAs, the victory established a collegiate standard. The emotionally-steely McClimon shed pools of tears. The sizable Michigan cheering section turned to bedlam. McGuire would find out later that evening, but* he was on everyone's minds as soon as Babcock finished. And now, one year or 10 years from now, the result will always be the same. "The bottom line is that when you look in the NCAA track program every year, for 1994, you're going to see that Michigan, with those four athletes, won the national championship in that event," McGuire says. "That's something that they'll always remember and I'll always remember." TEACH FOR AMERICA Applicants who have applied by the January 15, 1994 and March 2, 1994 deadlines are consideredfirst. Thank you to the thousands who have already applied! K&cfitron 's{ H Student Discounts! 320 S. State ocated in the lower level of Decker Drugs) Downstairs [ours: M, Tu, Th, Fr 9am- 6 pm wed.& Sat. 9am - 1pm Attention Graduating Seniors! W Exciting Sales Opportunities available with Detroit publishing company Gale Research, Inc., a major publisher of reference books for libraries and businesses worldwide, is seeking energetic, highly motivated individuals with a drive to succeed and the desire to join a dynamic, growth-oriented company. We offer the right individual the opportunity to: ,Work wMtoa professional d ,ntel Develop existing accounts and new business CaNin a defined territory Sel a broad range of new and estabshed product Competitive salary plus bonus. Complete benefit package indudes medical, dental and optical coverage, profit sharing, and retirement plan. Stimulating work environ- ment in prime downtown location. Customer or public cpntact experience helpful. Must enjoy working with people and have a pleasant, professional phone manner. Telemarketing training provided. To learn more about the aplication process and tell us about yourself, callour 24 hour line this week: (313)961-7880 CausS asles Recriter Or send your resume to: ma, h Equd OpporUy Employer Ip5OtrscO DeMOTM4226 THE MOST INTENSIVE COURSE FOR THE _ ! .1 .i D epd- I rov Contraceptive Injection (sterile medroxyprogesterone acetate suspension, USP) WHAT IS DEPO-PROVERA CONTRACEPTIVE INJECTION? DEPO-PROVERA Contraceptive Injection is a form of birth control that is given as an intra- muscular injection (a shot) in the buttock or upper arm once every 3 months. To continue your contraceptive protection, you must return for your next injection promptly at the end of 3 months. DEPO-PROVERA contains medroxyprogesterone acetate, a chemical similar to (but not the same as) the natural hormone progesterone, which is produced by your ovaries during the second halt of your menstrual cycle. DEPO-PROVERA acts by preventing your egg cells from ripening. If an egg is not released from the ovaries during your menstrual cycle, it cannot become fertilized by sperm and result in pregnancy. DEPO-PROVERA also causes changes in the lining of your uterus that make t less likely for pregnancy to occur. HOW EFFECTIVE IS DEPO-PROVERA CONTRACEPTIVE INJECTION? DEPO-PROVERA is over 99% effective, making it one of the most reliable methods of birth control available. This means that the average annual pregnancy rate is less than one for every 100 women who use DEPO-PROVERA. The effectiveness of most contraceptive methods depends in part on how reliably each woman uses the method. The effectiveness of DEPO-PROVERA depends only on the patient retuuming every 3 months for her next injection. Your health-care provider will help you compare DEPO-PROVERA with other con- traceptive methods and give you the information you need in order to decide which contra- ceptive method is the right choice for you. The following table shows the percent of women who got pregnant while using different kinds of contraceptive methods. It gives both the lowest expected rate of pregancy (the rate expected in women who use each method exactly as it should be used) and the typical rate of pregnancy (which includes women who became pregnant because they forgot to use their birth control or because they did not follow the directions exactly). PERCENT OF WOMEN EXPERIENCING AN ACCIDENTAL PREGNANCY IN THE FIRST YEAR OF CONTINUOUS USE Method Epected Typical DEPO-PROVERA 0.3 0.3 Implants (Norplant) 0.3 0.3 Female sterilization 0.2 0.4 Male sterilization 0.1 0.15 Oral contraceptive (pill) - 3 Combined0 Progestogen only 0.5 IUD- 3 Progestasert 2.0- Copper T 380A 0.8 - Condom (without spermicide) 2 12 Diaphragm (with spermicide) 6 18 Cervical Cap 6 18 Withdrawal 4 18 Periodic abstinence 1 -9 20 Spermicide alone 3 21 Vaginal Sponge used before childbirth 6 18 Used after childbirth 9 28 No method 85 85 Souce: Trussellet al; Obstet Gyncoai76:558,1990 WHO SHOULD NOT USE DEPO-PROVERA CONTRACEPTIVE INJECTION? Not all women should use DEPO-PROVERA. You should not use DEPO-PROVERA if you think you might be pregnant, have any vaginal bleeding without a known reason, have had cancer of the breast, have had a stroke, have or have had blood clots (phlebitis) in your leg, have problems with your liver or liver disease, or are allergic to DEPO- PROVE (medroxyprogesterone acetate or any of its other ingredients). You will have a physical examination before your doctor prescribes DEPO-PROVERA. It is important to tell your doctor if you are taking any prescription or over-the-counter medications or if you have a family history of breast cancer; an abnormal mammogram (breast x-ray), fibrocystic breast disease, breast nodules or lumps, or bleeding from your nipples; kidney disease; irregular or scanty menstrual periods; high blood pressure; migraine headaches; asthma; epilepsy (convulsions or seizures); diabetes or a family history of diabetes; or a occur and, therefore, the bleeding that comt..s with your normal menstruation does not take place. When you stop using DEPO-PROVERA your menstrual period will usually, in time, return to its normal cycle. 2. Bone Mineral Changes Use of DEPO-PROVERA may be associated with a decrease in the amount of mineral stored in your bones. This could increase your risk of developing bane fractures. The rate of bone mineral loss is greatest in the early years of DEPO-PROVERA use, but after that, it begins to resemble the normal rate of age-related bone mineral loss. 3. Cancer Studies of women who have used different forms of contraception found that women who used DEPO-PROVERA for contraception had no increased overall risk of developing cancer of the breast, ovary; uterus, cervix, or liver. However, women under 35 years of age whose first exposure to DEPO-PROVERA was within the previous 4 years may have a slightly increased risk of developing breast cancer similar to that seen with oral contraceptives. You should discuss this with your health-care provider. 4. Accidental Pregnancy Because DEPO-PROVERA is such an effective contraceptive method, the risk of accidental pregnancy for women who get their shots regularly (every 3 months) is very low. While there have been reports of an increased risk of low birth weight and neonatal infant death or other health problems in infants conceived close to the time of injection, such pregnancies are rare. If you think you may have become pregnant while using DEPO-PROVERA for con- traception, see your health-care provider as soon as possible. 5. Other Risks Women who use hormone-based contraceptives may have an increased risk of blood clots or stroke. Also, if a contraceptive method fails, there is a possibility that the fertilized egg will begin to develop outside of the uterus (ectopic pregnancy). While these events are rare, you should tell your health-care provider if you have any of the problems listed in the next section. WHAT SYMPTOMS MAY SIGNAL PROBLEMS WHILE USING DEPO-PROVERA CONTRACEPTIVE INJECTION? Call your health-care provider immediately if any of these problems occur following an injection of DEPO-PROVERA: Sharp chest pain, coughing of blood, or sudden shortness of breath (indicating a possible clot in the lung); sudden severe headache or vomiting, dizzi- ness or fainting, problems with your eyesight or speech, weakness, or numbness in an arm or leg (indicating a possible stroke): severe pain or swelling in the calf (indicating a possible clot in the leg); unusually heavy vaginal bleeding; severe pain or tenderness in the lower abdominal area; or persistent pain, pus, or bleeding at the injection site. WHAT ARE THE POSSIBLE SIDE EFFECTS OF DEPO-PROVERA CONTRACEPTIVE INJECTION? 1. Weight Gain You may experience a weight gain while you are using DEPO-PROVERA. About two thirds of the women who used DEPO-PROVERA in clinical trials reported a weight gain of about 5 pounds during the first year of use. You may continue to gain weight after the first year. Women in one large study who used DEPO-PROVERA for 2 years gained an average total of 8.1 pounds over those 2 years, or approximately 4 pounds per year. Women who contin- ued for 4 years gained an average total of 13.8 pounds over those 4 years, or approximate- ly 3.5 pounds per year. Women who continued for 6 years gained an average total of 16.5 pounds over those 6 years, or approximately 2.75 pounds per year. 2. Other Side Effects In a clinical study of over 3,900 women who used DEPO-PROVERA for up to 7 years, some women reported the following effects that may or may not have been related to their use of DEPO-PROVERA: Irregular menstrual bleeding, amenorrhea, headache, nervousness, abdominal cramps, dizziness, weakness or fatigue, decreased sexual desire, leg cramps, nausea, vaginal discharge or irritation, breast swelling and tendemess, bloating, swelling of the hands or feet, backache, depression, insomnia, acne, pelvic pain, no hair growth or excessiveshair loss, rash, and hot flashes. Other problems were reported by very few of the women in the clinical trials, but some of these could be serious. These include convulsions, jaundice, urinary tract infections, allergic reactions, fainting, paralysis, osteoporosis, lack of return to fertility, deep vein thrombosis, pulmonary embolus, breast cancer, or cervical can- cer. If these or any other problems occur during your use of DEPO-PROVERA, discuss them with your health-care provider. SHOULD ANY PRECAUTIONS BE FOLLOWED DURING USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION? 1. Missed Periods During the time you are using DEPO-PROVERA for contraception, you may skip a period, or your periods may stop completely. If you have been receiving your DEPO-PROVERA injections regularly every 3 months, then you are probably not pregnant. However, if you think that you may be pregnant, see your health-care provider. 2. Laboratory Test Interactions If you are scheduled for any laboratory tests, tell your health-care provider that you are using DEPO-PROVERA for contraception. Certain blood tests are affected by hormones such as DEPO-PROVERA. 3. Drug Interactions Cytadren (aminoglutethimide) is an anticancer drug that may significantly decrease the k A T Cofumfiia fJMCT eview Sering the U ofMfpre- medicaf community M.D. 'S TRAINING M.D.'S-OF-THE-FUTURE A Intensive MCAT preparation & medical school application/admissions assistance are all we do!. > MCAT experts: an independent course taught by academic M.D.'s, top U ofM M.D. & Ph.D. candidates, & English Department faculty. A 13 weeks (150+ hours) of detailed in-class instruction & real MCAT testing, problem solving, reading & writing workshops, review groups, med school application & admissions strategies, & tutoring. ) 2000 pages of original take-home review notes, reading & writing studyguides, MCAT & admissions strategy handouts, problem sets, & MCAT-quality timed practice exams. > Real MCAT testing for in-class & take-home practice. > Direct contact with young does & med students! > Tutoring & med school application help included. > Lower tuition than other courses. S 0